FOR IMMEDIATE RELEASE: May 28, 2020

CONTACT: Amy West, awest@tuftsmedicalcenter.org

BOSTON – Tufts Clinical and Translational Science Institute (CTSI) has joined the National COVID Cohort Collaborative (N3C), a collaboration of clinicians, informaticians and other biomedical researchers aims to turn data from hundreds of thousands of medical records from coronavirus patients into effective treatments and predictive analytical tools that could help lessen or end the global pandemic.

The N3C is a partnership among the National Center for Advancing Translational Sciences (NCATS)-supported Clinical and Translational Science Awards (CTSA) Program hubs and the National Center for Data to Health (CD2H), with overall stewardship by NCATS. Collaborators will contribute and use COVID-19 clinical data to answer critical research questions to address the pandemic.

Specifically, the N3C will enable the rapid collection and analysis of clinical, laboratory and diagnostic data from hospitals and health care plans. If successful, this approach will be applicable to other research questions and may serve as a model for addressing future public health emergencies.

For more information, please read the press release from Oregon Health and Science University, the home of CD2H.

Please also read the N3C Frequently Asked Questions (FAQs).

 

About Tufts Clinical and Translational Science Institute (CTSI)

Tufts Clinical and Translational Science Institute (Tufts CTSI), established in 2008, supported by the National Institutes of Health (NIH), is dedicated to stimulating innovative broadly-engaged team science across the translational research spectrum to improve clinical care and health. Founded by Tufts University and Tufts Medical Center, it also includes other academic institutions (including all the schools of Tufts University, Brandeis University, MIT, Northeastern University; and RAND), the hospitals affiliated with Tufts University School of Medicine, community stakeholders, and various members of the health care industry. Tufts CTSI’s purpose is to accelerate the translation of laboratory and medical research into clinical use, widespread medical practice, and into improved health care delivery and health policy. It connects people to research resources, consultation, and education, and fosters collaboration with scholars of all disciplines and with community members, with the ultimate goal of improving the health of the public. Tufts CTSI is funded by a Clinical and Translational Science Award (CTSA) from the NIH National Center for Advancing Translational Sciences, award number UL1TR002544.

#####

FOR IMMEDIATE RELEASE: May 28, 2020

CONTACT: Amy West, awest@tuftsmedicalcenter.org

BOSTON – Tufts Clinical and Translational Science Institute (CTSI) has joined the National COVID Cohort Collaborative (N3C), a collaboration of clinicians, informaticians and other biomedical researchers aims to turn data from hundreds of thousands of medical records from coronavirus patients into effective treatments and predictive analytical tools that could help lessen or end the global pandemic.

The N3C is a partnership among the National Center for Advancing Translational Sciences (NCATS)-supported Clinical and Translational Science Awards (CTSA) Program hubs and the National Center for Data to Health (CD2H), with overall stewardship by NCATS. Collaborators will contribute and use COVID-19 clinical data to answer critical research questions to address the pandemic.

Specifically, the N3C will enable the rapid collection and analysis of clinical, laboratory and diagnostic data from hospitals and health care plans. If successful, this approach will be applicable to other research questions and may serve as a model for addressing future public health emergencies.

For more information, please read the press release from Oregon Health and Science University, the home of CD2H.

Please also read the N3C Frequently Asked Questions (FAQs).

 

About Tufts Clinical and Translational Science Institute (CTSI)

Tufts Clinical and Translational Science Institute (Tufts CTSI), established in 2008, supported by the National Institutes of Health (NIH), is dedicated to stimulating innovative broadly-engaged team science across the translational research spectrum to improve clinical care and health. Founded by Tufts University and Tufts Medical Center, it also includes other academic institutions (including all the schools of Tufts University, Brandeis University, MIT, Northeastern University; and RAND), the hospitals affiliated with Tufts University School of Medicine, community stakeholders, and various members of the health care industry. Tufts CTSI’s purpose is to accelerate the translation of laboratory and medical research into clinical use, widespread medical practice, and into improved health care delivery and health policy. It connects people to research resources, consultation, and education, and fosters collaboration with scholars of all disciplines and with community members, with the ultimate goal of improving the health of the public. Tufts CTSI is funded by a Clinical and Translational Science Award (CTSA) from the NIH National Center for Advancing Translational Sciences, award number UL1TR002544.

#####